For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

The mNexspike vaccine is supplied as a single-dose prefilled syringe containing 1 dose of 0.2mL. The single 0.2mL dose should be administered at least 3 months after the last dose of COVID-19 vaccine.

Commonly reported AEs included injection site pain, fatigue, headache, and myalgia.1 Moderna also highlighted operational advantages, noting that improvements in storage, shelf life, and the use of a ...

HHS has terminated contracts with Moderna worth more than $700 million that were meant to fund the company’s development of pre-pandemic influenza vaccines, including the company’s H5 ...

US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a recommendation for mRESVIA, the company’s RSV vaccine available in a pre-filled syringe ...

Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, Norway, and North Macedonia. Read more here.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.

Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes.